Email Address
(this will be your username)
Full Name
Password Confirm Password Contact Number Country
EuroTimes Satellite Programme

Friday 13 September | 13:00 - 14:00

Lunchtime Symposia

Location: North 4
Limbal Stem Cells Deficiency due to Ocular Burns: The Patient’s Journey

Moderator(s): F. Figueiredo UK

  • F. Figueiredo UK
  • Introduction
  • F. Figueiredo UK
  • Ocular burns patients: where do they come from?
  • R. Nuijts The Netherlands
  • How to select patients eligible for Autologous Cultivated Limbal Stem Cells Transplantations (ACLSCT)?
  • P. Rama Italy
  • ACLSCT: results from clinical practice
  • F. Figueiredo UK
  • Q&A session

Saturday 14 September | 10:00 - 11:00

Morning Symposia

Location: North 4
Approaches to the Diagnosis and Management of Important Corneal Disorders in the Cataract and Refractive Patient

Moderator(s): B. Cochener-Lamard France

  • B. Cochener-Lamard France
  • Welcome, ARS and introduction
  • G. Kymionis Switzerland
  • Diagnostic imaging of the irregular corneas
  • B. Dick Germany
  • New technology for the detection of corneal disorders in the refractive surgery patient
  • A. Behndig Sweden
  • Evolving cross linking protocols for early intervention in patients with keratoconus and ectasia
  • M. Nubile Italy
  • Decision tree for the treatment of keratoconus and ectasia
  • Final Discussion, ARS and conclusion

The above programme is supported by an independent medical education grant from:

Avellino

Avedro

Saturday 14 September | 13:00 - 14:00

Lunchtime Symposia

Location: North 4
Ocular Surface Disease Diagnosis and Management: Special Focus on the Lipid Layer

Moderator(s): B. Cochener France J. Güell Spain

  • J. Güell Spain
  • Welcome, ARS & review of ESCRS clinical survey data
  • B. Cochener-Lamard France
  • Tear film instability: etiology, incidence, and impact on outcomes
  • J. M. Benítez del Castillo Sánchez Spain
  • Definition of the lipid layer and meibomian gland disease
  • C. Koppen Belgium
  • Diagnostic tools to assess the lipid layer and MGD
  • S. Doan France
  • Treatment options for the MGD patient
  • Panel Discussion
    Final ARS and conclusion


The above programme is supported by an independent medical education grant from:

Johnson and Johnson Vision

Shire

Santen
Alcon